ClinicalTrials.gg
TerminatedNCT00278824Updated Jun 5, 2012

Fentanyl Transdermal Patch With CHADD™ for Breakthrough Pain in Patients With Moderate to Severe Non-Malignant Pain

A Phase 2 interventional study of Matrix Transdermal Fentanyl/CHADD Drug Delivery System and Placebo Patch in Pain, sponsored by ZARS Pharma Inc.. Terminated at 15 sites in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2012-06-05.

Primary conditionChronic PainRegistry: PainReclassifiedWhy we changed it
Registry
Pain — the first condition term the registry derived for this study.
ClinicalTrials.gg
Chronic Pain
Why
  1. The study's title name Chronic Pain, a narrower term within Pain.
Confidence
High: the new condition is named in the study's own title. Of 46 hand-checked studies reclassified this way, 72% were exactly right and 89% in the right disease family; the registry's first term was right for 4% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by ZARS Pharma Inc. · Phase 2, Interventional, and Treatment

Why this study was terminated
Difficulty identifying and enrolling eligible patients

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
109
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,283 studies in Chronic Pain with a site in United States — 258 open to participants now, 349 under way, 7 of them phase 3. Chronic Pain · United States.

Enrollment
355th of 1,092
109 · median 60
Started
2006
with 16 others
Phase 2
87 of 1,283
19 open now
Registered
30th of 1,283
by date

Among the 1,283 studies in Chronic Pain with a site in United States, this one is the 355th largest by enrollment of the 1,092 interventional ones that give a count, is one of 17 that started in 2006, is one of 87 in phase 2, and was the 30th registered.

Chronic Pain

3,228 studies on the registry are indexed under Chronic Pain; 729 are open to participants now.

Browse Chronic Pain studies →

Open to participants now

258 of the 1,283 studies in Chronic Pain with a site in United States are open now. Recruiting first, the newest first:

253 more — sign in →

All 258 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 487 Chronic Pain studies recruiting now, 240 (49%) set no upper age limit and 173 (36%) stop at 75 or younger; 43 take children under 18; 64 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,283 studies in Chronic Pain with a site in United States, or all of them as a file.
02

Study summary

A multi-center study to evaluate the efficacy of CHADD (Controlled Heat-Assisted Drug Delivery) applied over a 50 mcg/hr ZR-02-01 matrix transdermal fentanyl patch for the treatment of breakthrough pain in adult patients with moderate to severe non-malignant chronic pain. The open-label study arm will last up to 12 days. The double-blind arm will last up to 15 days. Eligible patients who complete the open-label arm will be allowed to enroll in the double-blind study arm.

Read the detailed description

ZARS Pharma is developing a Matrix Transdermal Fentanyl/CHADD (Controlled Heat-Assisted Drug Delivery) Drug Delivery System to be used for the treatment of chronic and breakthrough pain. The Matrix Transdermal Fentanyl/CHADD Drug Delivery System has been designed to provide long-term delivery of fentanyl for the treatment of chronic pain as well as intermittent increases in fentanyl concentrations for the treatment of breakthrough pain. Breakthrough pain is defined as a transitory exacerbation of pain that occurs on a background of otherwise stable pain in a patient receiving chronic opioid therapy.

Matrix Transdermal Fentanyl/CHADD Drug Delivery System has 2 components: a matrix transdermal fentanyl patch (the ZR-02-01 patch in doses of 25, 50, 75 and 100 mcg/hr) with corresponding thin film dressing (ie, overlay) and the CHADD (Controlled Heat-Assisted Drug Delivery).

The matrix transdermal fentanyl patch provides a continuous delivery of fentanyl over 72 hours, in a manner similar to Duragesic®. During a breakthrough pain episode, a CHADD unit is placed over (adhered to) the matrix transdermal fentanyl patch. The CHADD is a thin patch-like chemical heating device that generates a controlled level of heat for approximately 15-20 minutes. The application of heat delivers increased amounts of fentanyl when applied over the ZR-02-01 matrix transdermal fentanyl patch.

03

Conditions studied

  • Pain

Browse trials for

Keywords

  • Chronic Pain
  • Pain
04

In context

Chronic Pain Reclassified

3,228 studies on the registry are indexed under Chronic Pain; 729 are open to participants now.

This study's enrollment of 109 is above the median of 60 across 2,388 interventional studies indexed under Chronic Pain.

Browse Chronic Pain studies →

Lead sponsor

ZARS Pharma Inc. is the lead sponsor of 24 studies on the registry; none are open to participants now.

Compared within Chronic Pain, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Pain. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient is 18 through 70 years of age.
  • Patient has moderate to severe non-malignant chronic pain.
  • Patient is opioid-tolerant, requires treatment with chronic opioids and is currently taking a dose of 50 mcg/hr transdermal fentanyl for the treatment of chronic pain. Patient must have been taking this dose for at least 2 weeks.
  • Patient must be experiencing 1 to 4 episodes of target breakthrough pain (breakthrough pain that is related to the patient's chronic pain condition) a day while taking a dose of 50 mcg/hr transdermal fentanyl.

Exclusion criteria

Exclusion Criteria:

  • Patient has active cancer.
  • Patient has a history of substance abuse or has a substance abuse disorder.
  • Patient is pregnant or breastfeeding.
06

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
109 participants (actual)

Study arms

  • Experimental
    50 mcg/hr matrix fentanyl patch

    active 50 mcg/hr ZR-02-01 matrix transdermal fentanyl patch (20 cm2)

    Drug: Matrix Transdermal Fentanyl/CHADD Drug Delivery System

  • Placebo comparator
    Placebo Patch

    placebo (20 cm2) will be indistinguishable in size, shape, and appearance to the active matrix fentanyl patch

    Drug: Placebo Patch

Interventions

  • DrugMatrix Transdermal Fentanyl/CHADD Drug Delivery System

    Patch applied every 3 days for 15 days

    Also known as: ZR-02-01, Fentanyl Transdermal Matrix Patch

  • DrugPlacebo Patch

    Placebo patch applied every 3 days for 15 days

    Also known as: Placebo Matrix Patch

07

What researchers measure

Primary outcomes

  1. Patient's rating of pain intensity (NRS), the patient's evaluation of pain relief using a 5-point verbal rating scale (VRS), and the patient's global satisfaction assessment.

    Efficacy will be evaluated by the patient's rating of pain intensity using an 11-point numerical rating scale (NRS), the patient's evaluation of pain relief using a 5-point verbal rating scale (VRS), and the patient's global satisfaction assessment.

    Time frame: 0, 15, 20, 60 minutes

Secondary outcomes

  1. Adhesion assessment

    An adhesion assessment will be conducted by the patient at each CHADD removal.

    Time frame: 3 days

  2. Pain Relief

    Patient's evaluation of pain relief using a 5-point verbal rating scale (VRS)

    Time frame: 15, 30, 60 minutes

  3. Patient's Global Satisfaction Assessment

    Patients completed a global satisfaction assessment 60 minutes after CHADD application. Patients were asked to assess their overall satisfaction with the CHADD throughout the 60 minute application period for the treatment of their breakthrough pain using the following 5-point scale: 0=not satisfied, 1=somewhat satisfied, 2=moderately satisfied, 3=very satisfied, and 4=completely satisfied.

    Time frame: 60 minutes

  4. Number of participants with adverse events

    The frequency of adverse events, severity, and relationship to study drug was recorded.

    Time frame: 15 days

08

Study locations

15 sites
  • Arizona Reserach Center
    Phoenix, Arizona 85023, United States
  • Florida's Institute of Clinical Research
    Jacksonville, Florida 32207, United States
  • Drug Studies America
    Marietta, Georgia 30060, United States
  • Pain & Rehabilitation Clinic of Chicago
    Chicago, Illinois 60610, United States
  • Integrated Clinical Trial Services, Inc.
    West Des Moines, Iowa 50265, United States
  • Brigham & Women's Hospital
    Boston, Massachusetts 02115, United States
  • Medical Advanced Pain Specialists
    Minneapolis, Minnesota 55433, United States
  • Pain Management Associates
    Independence, Missouri 64055, United States
  • Analgesic Development Ltd.
    New York, New York 10022, United States
  • Southeast Research Institute
    Charlotte, North Carolina 28203, United States
  • The Center for Clinical Research
    Winston-Salem, North Carolina 27103, United States
  • Pain Consultants of Oregon, PC
    Eugene, Oregon 97401, United States
  • Allegheny Pain Management
    Altoona, Pennsylvania 16602, United States
  • Lifetree Clinical Research
    Salt Lake City, Utah 84106, United States
  • Advanced Pain Management
    Virginia Beach, Virginia 23454, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2006, a primary completion of Aug 2006 and a completion of Aug 2006. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 16, 2006
First posted
Jan 18, 2006
Start
Jan 2006
Primary completionActual
Aug 2006
CompletionActual
Aug 2006
Last update
Jun 5, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 5, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00278824
Lead sponsor
ZARS Pharma Inc.
Responsible party
Sponsor
First posted
Jan 18, 2006
Start date
Jan 2006
Primary completion
Aug 2006
Completion
Aug 2006
Last update
Jun 5, 2012

Study contacts

Lynn R Webster, MD
principal investigator · Lifetree Clinical Research

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jun 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion